FindTrial
Sign In

Predictive performance of Smart Dose, PharmVan and JPKD on vancomycin plasma concentration

Predictive performance of Smart Dose, PharmVan and JPKD on vancomycin plasma concentration

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000039718
Enrollment
Unknown
Registered
2020-11-06
Start date
2020-11-20
Completion date
Unknown
Last updated
2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gram-positive bacterial infection

Interventions

Case Series:Case Series

Sponsors

The First Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adult patients (aged >= 18 years); 2. Monitor vancomycin steady-state trough concentration at least once.

Exclusion criteria

Exclusion criteria: 1. The subjects of hemofiltration, hemodialysis or peritoneal dialysis; 2. The subject of local use of vancomycin; 3. Subjects whose blood concentration did not reach steady state during TDM; 4. Subjects without weight information.

Design outcomes

Primary

MeasureTime frame
Plasma concerntration;Renal function;Age;Weight;—

Secondary

MeasureTime frame
Gender;albumin;clinical symptoms;—

Countries

China

Contacts

Public ContactYu Xuben

The First Affiliated Hospital of Wenzhou Medical University

yuxuben@126.com+86 13566216906

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026